Deconsolidation Of Lokahi And Discontinued Operations |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Discontinued Operations and Disposal Groups [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DECONSOLIDATION OF LOKAHI AND DISCONTINUED OPERATIONS | NOTE 3 — DECONSOLIDATION OF LOKAHI AND DISCONTINUED OPERATIONS
As described in Note 1, 51% of the equity of Lokahi was transferred to RXRR Capital Partners under the Settlement Agreement, and on July 14, 2026 Lokahi became a wholly owned subsidiary of Glucotrack. The Company no longer controls Lokahi and deconsolidated it in accordance with ASC 810-10-40. The Company elected to measure the deconsolidation using Lokahi’s June 30, 2026 balances. The gain on deconsolidation was measured as the fair value of the consideration received less the carrying amount of Lokahi’s net liabilities derecognized, as follows:
The Glucotrack securities were measured using Glucotrack’s closing price of $6.261 per share on July 14, 2026, or $0.4174 per share before Glucotrack’s 1-for-15 reverse stock split effective August 31, 2026. Share amounts above are stated before that reverse stock split. The Series A preferred stock, which had not been issued to the Company as of September 30, 2026, is measured on an as-converted basis. Lokahi’s net liabilities derecognized comprised total assets of $2,497,274, including cash of $53,186, and total liabilities of $9,337,992, including notes payable of $5,000,000, accrued interest of $1,240,350, notes payable — related party of $500,100 and operating lease liabilities of $161,396. The gain is included in income (loss) from discontinued operations.
Lokahi conducted the Company’s BioBusiness segment, which was the Company’s entire biopharmaceutical business and its only operating business before the acquisition of MindWave on December 1, 2025. The disposal represents a strategic shift that has a major effect on the Company’s operations and financial results, and the results of Lokahi are presented as discontinued operations for all periods presented. General corporate overhead has not been allocated to discontinued operations. Interest on Lokahi’s notes payable, which were obligations of Lokahi, is included in discontinued operations. The comparative 2025 periods are presented on the basis used in the segment disclosure in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, under which all operating expenses before December 1, 2025 were attributed to the BioBusiness; the change in fair value of the warrant liability, interest income and interest expense for those periods remain in continuing operations.
The results of discontinued operations were as follows:
Lokahi’s results for the six months ended June 30, 2026 include $1,281,090 of legal and consulting fees funded under the Settlement Agreement (see Note 7) and interest on Lokahi’s notes payable (see Note 8). General and administrative expense of discontinued operations for the three months ended September 30, 2026 consists of the reversal of stock-based compensation on unvested options forfeited by employees and consultants of Lokahi (see Note 10).
The assets and liabilities of discontinued operations as of December 31, 2025 were as follows. There were no assets or liabilities of discontinued operations as of September 30, 2026.
The Company presents the cash flows of discontinued operations combined with those of continuing operations in the condensed consolidated statements of cash flows. Cash of Lokahi of $53,186 derecognized on deconsolidation is presented within investing activities. Depreciation, amortization, capital expenditures and significant noncash items of the discontinued operations were as follows:
After the disposal, the Company’s continuing involvement with Lokahi consists of its investment in Glucotrack (Note 5), the Apitox royalty and revenue participation rights assigned by FreeT (Note 1), the San Diego office lease, which remains in the Company’s name (Note 13), and stock options of the Company held by former employees and consultants of Lokahi (Note 10).
License agreements. The Company’s license and supply arrangements with Apimeds, Inc. (Korea), a related party, relating to APITOX were part of the BioBusiness and are included in discontinued operations through the deconsolidation of Lokahi. No milestone payments became due and no royalty obligations were incurred during the three and nine months ended September 30, 2026 or 2025. After the disposal, the Company’s rights relating to Apitox consist of the royalty and revenue participation rights assigned by FreeT described in Note 1. Refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 for a description of the material terms of the license agreements. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||